Inclusion Criteria:

- Patients confirmed diagnosis of multiple myeloma with evaluable disease parameters
(1.Presence of M-protein in the serum and/or urine, 2.Increased plasma cells in the
bone marrow or biopsy-proven plasmacytoma, 3.Presence of related organ tissue
impairment)

- Patients with progression of disease after an initial response (complete, partial, or
minimal response based on the EBMT criteria) to at least 1 line of therapy.
Progression of disease before responding to an initial line of therapy with a
non-anthracycline containing regimen that included (at a minimum) an alkylating agent
or high-dose corticosteroids. Rituximab alone or experimental agents alone were not
to be considered a line of therapy

- Patients with progressive disease as defined by one of the following: i) > 25%
increase in M-protein, ii) Development of new or worsening lytic bone lesions, iii)
Development of new or worsening plasmacytoma, iv) Development of new or worsening
hypercalcemia (> 11.5 mg/dL or 2.8 mmol/L corrected) that is not attributable to any
other cause

- Patients with measurable secretory disease defined as either: i) Serum monoclonal
protein > 1 g/dL, ii) Urine monoclonal (light chain) protein > 200 mg/24 hours

- Patients with Eastern Cooperative Oncology Group (ECOG) performance status score of 0
or 1. ECOG performance status score 2 due to pain associated with bone disorder is
eligible.

Exclusion Criteria:

- Patients with history of treatment with bortezomib

- Patients with progressive disease while receiving an anthracycline-containing regimen

- Patients with no change (NC) in disease status during initial therapy (patient must
have had a response and then progression or progression while receiving initial
therapy [primary refractory disease]

- Patients with non-secretory disease (i.e., no measurable paraprotein in serum or
urine

- urine paraprotein level = 200 mg/24 hours)

- Patients with prior treatment with doxorubicin or other anthracycline at cumulative
doses greater than 240 mg/m2 (calculated using doxorubicin equivalent doses: 1 mg
doxorubicin = 1 mg JNS002 = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg
idarubicin)

- Patients with Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral
neuropathy, according to Common Terminology Criteria for Adverse Events (CTCAE)

- Patients with clinically significant heart disease, New York Heart Association (NYHA)
Class II or higher heart failure

- Patients with viral hepatitis or chronic liver disease

- Patients with pulmonary fibrosis or interstitial pneumonitis